10.1182/blood-2017-08-798322 - Blinatumomab for minimal residual dis...

This document has been corrected

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

10.1182/blood-2017-08-798322

Published Online: 2018-04-05

Journal: Blood•Publisher: American Society of Hematology

Authors: Albrecht Reichle•Carlos Graux•Christoph Faul•Dirk Nagorsen•Gerhard Zugmaier•Heinz-August Horst•Helmut Diedrich•Hendrik Wessels•Hervé Dombret•Jonathan E. Benjamin•Julia Stieglmaier•Massimiliano Bonifacio•Max S. Topp•Monika Brüggemann•Nicola Gökbuget•Ralf C. Bargou•Vincent Haddad•Violaine Havelange

This document has been corrected

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

10.1182/blood-2017-08-798322

Published Online: 2018-04-05

Journal: Blood

NOW

2019-06-13•Erratum

Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.

10.1182/blood.2019001109

* information provided by CrossRef

2019-06-13•Erratum

10.1182/blood.2019001109

* information provided by CrossRef

2018-04-05•Published

2019-06-13•Erratum

Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.

10.1182/blood.2019001109

* information provided by CrossRef

This document has been corrected

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

10.1182/blood-2017-08-798322

Published Online: 2018-04-05

Journal: Blood•Publisher: American Society of Hematology